Latest Breaking News On - Drug administration on nov - Page 6 : comparemela.com

Will COVID-19 treatment be Celltrion founder’s retirement legacy? Results of phase 2 clinical trial of coronavirus antibody agent set to be unveiled | Celltrion logo (Celltrion) Late on the front of coronavirus vaccine development and procurement, South Korea is pinning hopes on one particular company to provide the much-needed relief in this dark, pandemic winter Celltrion. The company is expected to announce in coming days results of its global clinical phase 2 trial of an anti-COVID-19 monoclonal antibody treatment candidate, CT-P59. Celltrion’s media-friendly founder and chairman Seo Jung-jin has said plenty of times that its drug, if approved, would “put an end” to the country’s struggles with the deadly virus.

South koreaCh ungch ong buktoDonald trumpEli lillySeo jung jinKorea ministry of foodDrug ministry in koreaVaccine initiativeJp morganDrug administration on novDrug administrationMiddle east respiratory syndromeDrug ministryNorth chungcheong provinceKee woo sungKim hyung ki